Chairman and CEO
Mr. Elam co-founded AntriaBio - now Rezolute - in October 2012 with Dr. Huh and Dr. Mantripragada, and brings to the company a rich background in management, operations, consulting, finance, and corporate law. He currently serves on the board of directors of Savara Pharmaceuticals in Austin, Texas as well as Aerogen, Inc. in Galway, Ireland.
Mr. Elam was previously CEO of AeroSurgical Limited, a European medical device company, and prior to that, had a very successful career at Nektar Therapeutics (NASDAQ: NKTR). He served as SVP and Head of the Pulmonary Business Unit where he managed a team of over 600 professionals and various partnerships with large pharmaceutical companies. He successfully worked with members of his scientific team at Nektar to spin out Pearl Therapeutics to focus on treatments for asthma and COPD (in 2013 Pearl Therapeutics was acquired by AstraZeneca for $1 billion). In 2008, he negotiated the sale of the pulmonary business unit at Nektar to Novartis for $200 million enterprise value.
Prior to his role at Nektar, Mr. Elam was CFO and co-founder of E2open, (NASDAQ: EOPN), an IT platform company serving the electronics and healthcare industries where, in addition to managing finance and corporate and business development, he established operations in five locations in Asia including Singapore, Kuala Lumpur, Taipei, Tokyo, and Seoul.
In the 1990s, Mr. Elam had a successful career at the venerable law firm of Wilson Sonsini Goodrich & Rosati in Palo Alto, California where he was a partner in the corporate practice. He worked with companies in a variety of industries including healthcare, where his clients ranged from large biotech organizations such as Genentech to small novel therapeutic companies in the US and Europe. Mr. Elam advised clients on a range of matters including debt and equity financings, FDA issues, acquisitions, partnerships and cross-border transactions. He also served clients such as Hewlett Packard and Sun Microsystems and notably, in 1997 he negotiated the sale of Steve Jobs' company, Next, to Apple.
Mr. Elam received his B.A. from Howard University and his J.D. from Harvard Law School.
Chief Scientific Officer
As the author and inventor of over 70 publications and patents, Dr. Mantripragada is a widely recognized expert in long-acting injectable therapies with demonstrated success in the discovery and development of a number of commercially marketed drugs, including Exparel®, Depocyt® and Xcience®. He designed and developed Locemia Solutions' intranasal glucagon, the first potential needle-free rescue treatment for severe hypoglycemia that was recently acquired by Eli Lilly and Company. Prior to co-founding AntriaBio - now Rezolute - with Mr. Elam & Dr. Huh, Dr. Mantripragada served as Vice President and Head of Research & Development at PR Pharmaceuticals, Inc. Throughout his career, Dr. Mantripragada has served as an advisor to several companies specializing in diabetes, cell based therapies and cardiovascular diseases. His prior roles include Director of Research & Development at Guidant Corporation (now part of Abbott Vascular), as well as Director of Research & Development and Vice President of Scientific Development at SkyePharma (now Pacira Pharmaceuticals). Prior to transitioning to the pharmaceutical industry, Dr. Mantripragada was Assistant Professor of Biochemistry at the University of Virginia School of Medicine. His training includes a Ph.D. in Molecular Biophysics from the Indian Institute of Science and postdoctoral research at the Max Planck Institute for Biophysical Chemistry in Germany.
Chief Financial Officer
Dr. Vendola previously served as Vice President of Competitive Strategy and Chief of Staff at Coherus BioSciences while the market cap exceeded $1 billion. In this role, he interacted extensively with Wall Street and executed multiple financings. In addition, he has served in senior finance and corporate development roles at a variety of pharmaceutical companies and as an investment banker within the healthcare groups of Banc of America Securities and Chase. As an executive and investment banker, he has contributed to many transactions and helped companies raise over $850 million.
Dr. Vendola received an M.B.A. in finance from Northwestern’s Kellogg School of Management, M.D. from Dartmouth Medical School and B.A. in psychology from the College of the Holy Cross, where he graduated with honors. He completed an executive education program at Harvard Business School focused on strategic negotiations as well as a research fellowship in the Developmental Endocrinology Branch of the National Institutes of Health, where he was an author on multiple papers.
VP, Clinical Development
Prior to joining AntriaBio - now Rezolute - Dr. Roberts directed clinical development at Fibrogen, Inc, where he helped successfully launch the global Phase 3 program and pharmaceutical partnership for a novel oral therapy for anemia associated with kidney disease. From 2007 until 2012 Dr. Roberts held clinical development positions of increasing responsibility at Metabolex, Inc., where he developed novel therapies for metabolic diseases such as diabetes, dyslipidemia, and gout. His program and clinical leadership from IND through clinical proof-of-concept helped secure a global licensing and co-development agreement with a major pharmaceutical partner for a novel diabetes therapy. He is an inventor or author on more than 20 patents and publications in the fields of Endocrinology and Metabolism. Dr. Roberts received his B.S. in biochemistry from the University of California, San Diego and his medical degree Magna Cum Laude from Georgetown University. He completed residency in Internal Medicine and fellowship in Endocrinology at Stanford University, where he also now serves as Adjunct Associate Professor in the Division of Endocrinology.
Prior to joining AntriaBio - now Rezolute - in January 2016, Mr. Deperro spent the past two decades in technical operations leadership roles within large pharma, biotech, generics and in a contract development and manufacturing capacity. A Mechanical Engineer from the University of Notre Dame and former US Army Officer, Mike's early career focused on the implementation of manufacturing and research infrastructure in the US and Ireland for companies including Schering Plough, Merck and Novartis. Transitioning from pharmaceutical engineering to operations management, Mike directed the startup of a generic parenterals business unit, focusing on plant establishment, product development and support of product launch for global markets. As Director of Manufacturing at Alkermes, Mike's manufacturing operation supported global sales of Risperdal® Consta®, the launch of Vivitrol® and delivery of Phase 3 supplies for Bydureon®, all commercialized controlled release formulations utilizing injectable microsphere technologies. These commercial manufacturing operations encompassed polymerization, bulk sterile microsphere manufacture and aseptic fill finish for US and ROW markets. Most recently, as General Manager for GMP Operations at Bend Research, and Vice President of Operations for Agere Pharmaceuticals, Mike led specialized teams charged with the delivery of early phase clinical supplies for complex, poorly soluble molecules in fast-paced multi-client environments. Mike's passion for leadership, integration of complex technologies and a strong belief in positive patient outcomes provide a strong foundation for the development of sustainable operations at Rezolute.
Director of Clinical Development
Dr. Ferrara-Cook joined Rezolute as Director of Clinical Development in May 2018. Prior to this appointment, she established and served as co-director of a regional treatment center for patients with CHI at the University of California, San Francisco (UCSF). She brings to Rezolute a wealth of experience as a Principal Investigator on industry and government-sponsored clinical trials. Dr. Ferrara-Cook completed her Pediatrics Residency and Endocrinology Fellowship at Children’s Hospital of Philadelphia (CHOP), an internationally recognized referral center for CHI patients, under the thought leadership and training of Drs. Diva D. De León-Crutchlow and Charles A. Stanley, also highly regarded key opinion leaders in CHI. Dr. Ferrara-Cook received a M.D. and Ph.D. from Duke University School of Medicine and maintains an Adjunct Assistant Professor position at UCSF where she continues to see patients with CHI.